News

CDMOs Announce Strategic Partnership for Fully Integrated Manufacturing Solutions

June 25, 2024

The pairing of Abzena and Argonaut Manufacturing Services is the result of several years’ worth of collaborative work between the two companies.

WHO Warns About Falsified Ozempic Batches

June 24, 2024

This alert follows a similar one from the European Medicines Agency in October 2023 amid a rise in demand for the diabetes medication that, in turn, created a shortage.

USP and African Institutions Provide Free Access to Pharma Production Resources

June 24, 2024

A new initiative will advance access to quality medicines and vaccines in Africa.

Bora Pharmaceuticals Acquires Baltimore Manufacturing Facility from Emergent

June 21, 2024

The transaction, announced June 20, follows Bora’s purchase of Minnesota-based Upsher-Smith Laboratories earlier in 2024.

AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients

June 20, 2024

Imfinzi (durvalumab) combined with chemotherapy decreased the risk of disease progression or death by 58% in a 700-patient trial.

CordenPharma and WACKER Consortium Enters Pandemic Readiness

June 20, 2024

The companies have completed the expansion and qualification phase and now enter a stand-by phase for five years.

Thermo Fisher Opens New Building at Wisconsin GMP Lab

June 19, 2024

The $58 million investment has resulted in a 72,000-square-foot facility with a dedicated LC–MS space and molecular suites and will bring as many as 350 new jobs onto the campus.

EMA Reviews Risks of CAR T-Cell Medicines and Painkillers

June 19, 2024

PRAC is reviewing the risk of secondary malignancies in patients treated with CAR T-cell medicines.

FDA Approves Immunoglobulin Therapeutic to Treat Primary Immunodeficiencies

June 18, 2024

Yimmugo, which was introduced in Europe at the end of 2022, could be on the market in the US within months.

Roche and Ascidian Therapeutics Collaborate on Treatments for Neurological Diseases

June 18, 2024

The research collaboration and licensing agreement will focus on the discovery and development of RNA exon editing therapeutics.